Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project

Milena Sant*, Claudia Allemani, Carmen Tereanu, Roberta De Angelis, Riccardo Capocaccia, Otto Visser, Rafael Marcos-Gragera, M. Maynadie, Arianna Simonetti, Jean Michel Lutz, Franco Berrino, M. Hackl, J. Holub, M. Maynadie, B. Holleczek, L. Tryggvadottir, H. Comber, F. Bellù, A. Giacomin, S. FerrettiE. Crocetti, D. Serraino, M. Vercelli, M. Federico, M. Fusco, M. Michiara, R. Tumino, L. Mangone, F. Falcini, A. Iannelli, M. Budroni, R. Zanetti, S. Piffer, F. La Rosa, P. Zambon, S. Sowe, K. England, F. Langmark, J. Rachtan, R. Mezyk, M. Zwierko, M. Ondrusova, M. Primic-Žakelj, S. Khan, G. Jundt, M. Usel, S. M. Ess, A. Bordoni, M. Roche, A. Gavin

*Corresponding author for this work

Research output: Contribution to journalArticle

443 Citations (Scopus)


Changing definitions and classifications of hematologic malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest World Health Organization classification and useful for epidemiologic and public health purposes. We present crude, age-specific and age-standardized incidence rates for European HMs according to these groupings, estimated from 66 371 lymphoid malignancies (LMs) and 21 796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardized incidence rates were 24.5 (per 100 000) for LMs and 7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.62), small B-cell lymphocytic lymphoma/chronic lymphatic leukemia (3.79), diffuse B-cell lymphoma (3.13), and Hodgkin lymphoma (2.41). The commonest MMs were acute myeloid leukemia (2.96), other myeloproliferative neoplasms (1.76), and myelodysplastic syndrome (1.24). Unknown morphology LMs were commonest in Northern Europe (7.53); unknown morphology MMs were commonest in Southern Europe (0.73). Overall incidence was lowest in Eastern Europe and lower in women than in men. For most LMs, incidence was highest in Southern Europe; for MMs incidence was highest in the United Kingdom and Ireland. Differences in diagnostic and registration criteria are an important cause of incidence variation; however, different distribution of HM risk factors also contributes. The quality of population-based HM data needs further improvement.

Original languageEnglish
Pages (from-to)3724-3734
Number of pages11
Issue number19
Publication statusPublished - 11 Nov 2010
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project'. Together they form a unique fingerprint.

  • Cite this

    Sant, M., Allemani, C., Tereanu, C., De Angelis, R., Capocaccia, R., Visser, O., Marcos-Gragera, R., Maynadie, M., Simonetti, A., Lutz, J. M., Berrino, F., Hackl, M., Holub, J., Maynadie, M., Holleczek, B., Tryggvadottir, L., Comber, H., Bellù, F., Giacomin, A., ... Gavin, A. (2010). Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. Blood, 116(19), 3724-3734.